12,372 trials
Hematological Malignancies · Acute Lymphoblastic Leukemia (ALL) · Acute Myelogenous Leukemia (AML)
Primary: Time to Neutrophil Engraftment — 12; 22 days
HIV Prevention
Primary: The Safety Profile of the 25 mg Dapivirine Vaginal Ring-004, When Inserted at Monthly Intervals. Participants Attended RC at Monthly Visits (up to Max of Three Monthly…
Epilepsy
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 77.2 percentage of participants
Human Immunodeficiency Virus
Primary: The Safety Profile Associated With the Open-label Use of the Dapivirine Vaginal Matrix Ring (25 mg) in Women — 52; 19; 2 Participants
Major Depressive Disorder
Primary: Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) — -11.5; -14.1; -13.1 score on a scale — p=0.0050
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) — -3.53; -3.54 score on a scale
Paroxysmal Nocturnal Hemoglobinuria
Primary: Number of Subjects Who Achieved Hemoglobin (Hb) Stabilization — 30; 0 Participants — p=<0.0001
Pneumococcal Infections
Primary: Adult Participants: Percentage of Participants With a Solicited Injection-site Adverse Event Following Any of the First 3 Doses With V114 or Prevnar 13™ — 20.6; 14.0…
Paroxysmal Nocturnal Hemoglobinuria
Primary: Ctrough Serum Concentration of Ravulizumab — 457.58; 578.70 micrograms/milliliter (µg/mL) — p=<0.0001
Dravet Syndrome
Primary: Change in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) Period — -3.18; -0.65 Convulsive seizures…
Dravet Syndrome · Seizure Disorder
Primary: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8…
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 — -0.011; 0.091 percentage of HbA1c — p==0.782
Breast Cancer
Primary: Invasive Disease-free Survival in Hormone Receptor (ER and PgR) Positive Sub-groups — 86.5; 85.9 percentage of patients without event — p=0.93
Chronic Plaque Psoriasis
Primary: Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale — 99; 9 Participants — p=<0.0001
Covid19 · Coronavirus
Primary: Number of Participants With Clinical Deterioration — 13; 15 Participants